Somatotropin biobetter - Ahn-Gook Pharma

Drug Profile

Somatotropin biobetter - Ahn-Gook Pharma

Alternative Names: AG B1512; Somatotropin biobetter

Latest Information Update: 04 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ahn-Gook Pharmaceutical
  • Class Growth hormones
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Growth disorders

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Growth disorders in South Korea (IV)
  • 01 Apr 2017 Preclinical trials in Growth disorders in South Korea before April 2017 (SC)
  • 01 Apr 2017 Pharmacodynamics and pharmacokinetics data from preclinical study in Growth disorders presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top